Blonanserin is used to treat schizophrenia in Japan and South Korea but not in the US. Blonanserin, sold under the brand name Lonasen.. Reference standards of Blonanserin API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below
Blonanserin
Catalogue No.:PA 29 18000
CAS :
Molecular Formula : C23H30FN3
Molecular Weight : 367.50
Blonanserin-d5
Catalogue No.:PA STI 013730
Molecular Formula : C23H25D5FN3
Molecular Weight : 372.53
Blonanserin N-Oxide
Catalogue No.:PA 29 0181000
Molecular Formula : C23H30FN3O
Molecular Weight : 383.5
4-(4-Fluorophenyl)-2-(4-nitrosopiperazin-1-yl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
Catalogue No.:PA 29 0181001
Molecular Formula : C21H25FN4O
Molecular Weight : 368.46
2-(4-Ethylpiperazin-1-yl)-4-(4-(4-ethylpiperazin-1-yl)phenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
Catalogue No.:PA 29 0181002
Molecular Formula : C29H43N5
Molecular Weight : 461.7
Blonanserin C
Catalogue No.:PA 29 0181003
Molecular Formula : C21H26FN3
Molecular Weight : 339.46
2-(4-Ethylpiperazin-1-yl)-4-(4-methoxyphenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
Catalogue No.:PA 29 0181009
Molecular Formula : C24H33N3O
Molecular Weight : 379.55
2-(4-Ethylpiperazin-1-yl)-4-phenyl-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
Catalogue No.:PA 29 0181004
Molecular Formula : C23H31N3
Molecular Weight : 349.52
4-(4-Chlorophenyl)-2-(4-ethylpiperazin-1-yl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
Catalogue No.:PA 29 0181005
Molecular Formula : C23H30ClN3
Molecular Weight : 383.96
Methyl 4-fluorobenzoate
Catalogue No.:PA 29 0181006
Molecular Formula : C8H7FO2
Molecular Weight : 154.14
2-Chloro-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
Catalogue No.:PA 29 0181007
Molecular Formula : C17H17ClFN
Molecular Weight : 289.78
4-(4-Fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridin-2(1H)-one
Catalogue No.:PA 29 0181008
Molecular Formula : C17H18FNO
Molecular Weight : 271.34
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
